Abstract

The basic reason for the failure of clinical trials is an inability to demonstrate efficacy and reasonable safety. Most of the clinical trials show failure when a significant sample size of patients is included and when the statistical analysis shows that the new drug either is not efficacious or has high side effects. Companies are also reluctant, to market molecules of similar efficacy as there is always a challenge for marketing. Recently more biologicals have failed, which were developed by various European Biotech companies.